Table 1.
Polyclonal antibody preparations and sera used for treatment of botulism.
| Preparation Name | BoNT Type Neutralized | Company | Antitoxin Titer | Recommended Dose |
|---|---|---|---|---|
| BAT-AB and BAT-E | A, B and E | Sanofi Pasteur | BoNT Type/Neutralizing Units/mL | Expired in 2010 |
| Heptavalent equine anti-toxin (HBAT) | A–G | Cangene Corporation (USA) | BoNT/A 4500 BoNT/B 3300 BoNT/C 3000 BoNT/D 600 BoNT/E 5100 BoNT/F 3000 BoNT/G 600 |
1 vial (adult > 17 years) 20–100% of adult dose for pediatric (1–17 years) 10% of adult dose for infants (<1 year) |
| Trivalent equine anti-toxin | A, B, E | Behring (Germany) | BoNT/A 187500 BoNT/B 125000 BoNT/E 12500 |
2 bottles |
| Trivalent equine anti-toxin | A, B, E | Biomed (Poland) | BoNT/A 5000 BoNT/B 5000 BoNT/E 1000 |
1–5 vials |
| Trivalent equine anti-toxin | A, B, E | Instituto Butantan (Brazil) | BoNT/A 7500 BoNT/B 5500 BoNT/E 5000 |
1 vial |
| Bivalent equine anti-toxin EqBA | A, B | Argentina Public Department of Health | BoNT/A 7500 BoNT/B 5500 |
1 vial |
| Tetravalent equine anti-toxin |
A, B, E, F | Chiba Serum (Japan) | BoNT/A 10000 BoNT/B 10000 BoNT/E 10000 BoNT/F 4000 |
1–3 vials |
| Human botulism immune globulin (Baby-BIG)† |
A, B | California Department of Public Health (USA) |
BoNT A 15 BoNT/B 4 |
Infant (<1 year) 1 ml/kg of body weight |
†: BabyBIG is no longer produced as described in the text, the future BabyBIG formulation will be based on a bi-valent receptor binding domain vaccine to BoNT/A and /B only [33]. BoNT: botulinum neurotoxin,